NIH PAR · NCI · U34
PAR-25-103: Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
Reviewed by Dr. Meng ZhaoLast reviewed October 16, 2026Data refreshed October 16, 2026Editorial standards
The purpose of this NOFO is to facilitate well planned clinical trials across the cancer prevention and control spectrum aimed at improving prevention/ interception, cancer-related health behaviors, screening, early detection, healthcare delivery, management of treatment-related symptoms, supportive care, and the long-term outcomes of cancer survivors. Although the scientific literature or preliminary data may provide the rationale for conducting a clinical trial, investigators often lack critical information about the study population, accrual challenges, intervention, outcome/ endpoints, data/statistical challenges or operational risks necessary to finalize the trial protocol completely.…
- NOFO number
- PAR-25-103
- Type
- PAR
- Activity code
- U34
- Primary institute
- NCI · National Cancer Institute
- Clinical trials
- Optional
- Posted
- Nov 5, 2024
- Opens
- Jan 25, 2025
- Expires
- Oct 26, 2027
PAR-25-103 due dates
4 application due dates remain before the NOFO expires. Dates marked * are NIH standard due dates. Check the related notices below for changes NIH made after posting.
| Application Due Date(s) | Renewal / Resubmission / Revision (as allowed) | AIDS - New/Renewal/Resubmission/Revision, as allowed | Scientific Merit Review | Advisory Council Review | Earliest Start Date |
|---|---|---|---|---|---|
| February 25, 2025 | February 25, 2025 | Not Applicable | July 2025 | October 2025 | December 2025 |
| June 25, 2025 | June 25, 2025 | Not Applicable | November 2025 | January 2026 | April 2026 |
| October 25, 2025 | October 25, 2025 | Not Applicable | March 2026 | May 2026 | July 2026 |
| February 25, 2026 | February 25, 2026 | Not Applicable | July 2026 | October 2026 | December 2026 |
| June 25, 2026 | June 25, 2026 | Not Applicable | November 2026 | January 2027 | April 2027 |
| October 25, 2026 | October 25, 2026 | Not Applicable | March 2027 | May 2027 | July 2027 |
| February 25, 2027 | February 25, 2027 | Not Applicable | July 2027 | October 2027 | December 2027 |
| June 25, 2027 | June 25, 2027 | Not Applicable | November 2027 | January 2028 | April 2028 |
| October 25, 2027 | October 25, 2027 | Not Applicable | March 2028 | May 2028 | July 2028 |
Projects funded under PAR-25-103
NIH RePORTER lists 2 projects funded under PAR-25-103 in FY2022–FY2026, with $703K in award dollars. Counts include each project's later non-competing years, which keep the original NOFO number.
Projects funded
2
Distinct projects, FY2022–FY2026
New awards
2
Type 1 (new project) award records
NIH funding
$703K
Award dollars under PAR-25-103, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 0 | 0 | $0 |
| FY2024 | 0 | 0 | $0 |
| FY2025 | 0 | 0 | $0 |
| FY2026 | 2 | 2 | $703K |
Institutions with the most funding
- Children's Hosp of Philadelphia$427K · 1 project
- University of Rochester$276K · 1 project
Funding institutes
- NCI$703K · 2
Activity codes funded
- U342 records
Most recent new awards
- Cancer screening with cell-free DNA in Li-Fraumeni Syndrome: Feasibility study prior to national trial (opens NIH RePORTER)
Children's Hosp of Philadelphia · 1U34CA308743-01 · NCI · Notice Jul 16, 2026
$427KU34
- Whole Food Plant-Based Lifestyle Adaptation for Nutrition Therapy in Patients with Metastatic Breast Cancer: The PLANT-MBC Study in NCORP (opens NIH RePORTER)
University of Rochester · 1U34CA304677-01A1 · NCI · Notice Jul 7, 2026
$276KU34
What its predecessor PAR-22-174 funded
PAR-25-103 reissues PAR-22-174. Its funding history is the best guide to who wins under this program: 3 projects and $2.4M in FY2022–FY2026.
Projects funded
3
Distinct projects, FY2022–FY2026
New awards
3
Type 1 (new project) award records
NIH funding
$2.4M
Award dollars under PAR-22-174, FY2022–FY2026
Funding by fiscal year
| Fiscal year | Award records | New awards | Funding |
|---|---|---|---|
| FY2022 | 0 | 0 | $0 |
| FY2023 | 1 | 1 | $284K |
| FY2024 | 2 | 1 | $564K |
| FY2025 | 3 | 1 | $911K |
| FY2026 | 2 | 0 | $656K |
Institutions with the most funding
- Wake Forest University Health Sciences$1.4M · 2 projects
- Dana-Farber Cancer Inst$1.0M · 1 project
Funding institutes
- NCI$2.4M · 8
Activity codes funded
- U348 records
Most recent new awards
- Collaborative Oncology: Preparing for a Multisite Trial to Facilitate Communication between Radiation Oncologists and Radiologists in Cancer Treatment Planning and Surveillance (opens NIH RePORTER)
Wake Forest University Health Sciences · 1U34CA297499-01 · NCI · Notice Apr 30, 2025
$248KU34
- Distance-based Exercise to preserve Function and prevENt Disability (DEFEND) (opens NIH RePORTER)
Dana-Farber Cancer Inst · 1U34CA293568-01 · NCI · Notice Sep 18, 2024
$295KU34
- Multi-site Community Oncology Planning for the CONNECT Intervention Targeting Lung Cancer Caregivers (opens NIH RePORTER)
Wake Forest University Health Sciences · 1U34CA283478-01 · NCI · Notice Jun 19, 2023
$284KU34
FY2026 closed on September 30, 2026, but NIH keeps posting that year's awards to RePORTER for several weeks. FY2026 figures reflect records available on October 16, 2026 and may rise slightly at the next refresh.
Participating institutes
2 NIH institutes and offices take applications under PAR-25-103. Contact the program officer at the institute that fits your research before applying.
- NCI · National Cancer Institute
- none
Related notices
Mar 31, 2025 · NOT-OD-24-084
This funding opportunity was updated to align with agency priorities. Carefully reread the full funding opportunity and make any needed adjustments to your application prior to submission.April 4, 2024 - Overview of Grant Application and Review Changes for Due Dates on or after January 25,…
Aug 31, 2022 · NOT-OD-22-198
Implementation Changes for Genomic Data Sharing Plans Included with Applications Due on or after January 25, 2023. See Notice NOT-OD-22-198.
Aug 5, 2022 · NOT-OD-22-189
Implementation Details for the NIH Data Management and Sharing Policy. See Notice NOT-OD-22-189.
Notices of Special Interest (NOSIs)
NIH has attached 4 NOSIs to PAR-25-103; none are active now. A NOSI flags a topic an institute wants to fund through this NOFO.
Award terms
- Application types allowed
- NewResubmission The OER Glossary and the How to Apply Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO.
- Award budget
- Application budgets are limited to 225,000 per year and 450,000 in direct costs over the 3-year project period without a clinical trial.Applications that include a pilot/ feasibility clinical trial are limited to 225,000 per year and 600,000 in direct costs over the 3-year project period.
- Project period
- The maximum project period is three years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
- Funds available and number of awards
- The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Summarized from the NOFO text; the full NOFO governs eligibility, budget, and review.
Related NOFOs
- Reissue of PAR-22-174.
- Companion NOFOs: PAR-25-104.
About this page
GotGrant gathers the NOFO, its participation and change notices, and its NOSIs from the NIH Guide for Grants and Contracts, and counts funded projects from NIH RePORTER by the opportunity number each award was made under. Data refreshed October 16, 2026; the NIH Guide is the authoritative source. See our data methodology.